Ann: CBD Products to Become Available Over the Counter, page-37

@mattstambe

Whether a stock is undervalued or not depends on assessment, and assessment is a variable with wide variance the more nascent the company and industry. AGH and the cannabis industry are both in their early days.

Naturally, anyone holding the stock (as you claim to) believes there is value in this industry, and in this stock.
If you believe AGH is overvalued right now, why do you still hold it? Selling will do you far more good, according to your professed beliefs, than complaining here and insulting people.

You claim AGH have no discernible assets.

- They have an Australian Register of Therapeutic Goods-approved medical device product (their online educational, relationship-building and telesales platform) which has grown the business to the point of delivering almost 700k in revenue in a single month (July 2020)
- They have an extraction facility with a client lined up (assets don't cease to be assets just because they are brand new and have not yet been used, just so you know)
- They have a significant inventory of product.
- They have rapidly growing network of doctors and patients in two countries, and a distribution agreement for their products in a third.
- Last but not least, they have a brand that is one of the most recognised in Australia in this nascent industry with huge potential.

But no... no discernible assets... LOL...